Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report)'s stock price dropped 4.7% on Thursday . The stock traded as low as $20.33 and last traded at $20.33. Approximately 20,892 shares traded hands during trading, a decline of 74% from the average daily volume of 79,801 shares. The stock had previously closed at $21.34.
A number of research analysts recently commented on the stock. Leerink Partnrs raised shares of Oruka Therapeutics to a "strong-buy" rating in a research report on Tuesday, September 17th. TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a "buy" rating on the stock. Lifesci Capital began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an "outperform" rating and a $41.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Monday, November 25th. Finally, Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a "buy" rating and a $40.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $43.17.
Get Our Latest Stock Report on ORKA
The firm's fifty day moving average is $24.77. The company has a market capitalization of $716.78 million, a price-to-earnings ratio of -3.27 and a beta of 0.78.
Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at about $343,000. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics in the third quarter valued at about $1,037,000. Wellington Management Group LLP purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at approximately $2,013,000. Janus Henderson Group PLC purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at approximately $5,840,000. Finally, Redmile Group LLC acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $10,091,000. 56.44% of the stock is owned by institutional investors and hedge funds.
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.